Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paris Kosti

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|June 7, 2018
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid TumorsParis Kosti, John Maher, James N Arnold
STAR Protocols|August 17, 2021
Generation of hypoxia-sensing chimeric antigen receptor T cellsParis Kosti, Karen I Larios-Martinez, John Maher, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Generation and Characterization of CAR-T CellsSarah Ash, Greta Maria Paola Giordano Attianese, Paris Kosti, et al.
The Journal of Experimental Medicine|November 6, 2020
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpressionEvripidis Lanitis, Giorgia Rota, Paris Kosti, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor bindingEvripidis Lanitis, Paris Kosti, Catherine Ronet, et al.
Journal for Immunotherapy of Cancer|March 13, 2025
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engagerParis Kosti, Johan Abram-Saliba, Laetitia Pericou-Troquier, et al.
Nature Communications|July 29, 2018
Macrophages are exploited from an innate wound healing response to facilitate cancer metastasisTamara Muliaditan, Jonathan Caron, Mary Okesola, et al.
Cell Reports. Medicine|May 5, 2021
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumorsParis Kosti, James W Opzoomer, Karen I Larios-Martinez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2018
Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of CancerTamara Muliaditan, James W Opzoomer, Jonathan Caron, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|June 7, 2018
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid TumorsParis Kosti, John Maher, James N Arnold
STAR Protocols|August 17, 2021
Generation of hypoxia-sensing chimeric antigen receptor T cellsParis Kosti, Karen I Larios-Martinez, John Maher, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Generation and Characterization of CAR-T CellsSarah Ash, Greta Maria Paola Giordano Attianese, Paris Kosti, et al.
The Journal of Experimental Medicine|November 6, 2020
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpressionEvripidis Lanitis, Giorgia Rota, Paris Kosti, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor bindingEvripidis Lanitis, Paris Kosti, Catherine Ronet, et al.
Journal for Immunotherapy of Cancer|March 13, 2025
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engagerParis Kosti, Johan Abram-Saliba, Laetitia Pericou-Troquier, et al.
Nature Communications|July 29, 2018
Macrophages are exploited from an innate wound healing response to facilitate cancer metastasisTamara Muliaditan, Jonathan Caron, Mary Okesola, et al.
Cell Reports. Medicine|May 5, 2021
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumorsParis Kosti, James W Opzoomer, Karen I Larios-Martinez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2018
Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of CancerTamara Muliaditan, James W Opzoomer, Jonathan Caron, et al.
Pageof 1